Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial

BACKGROUND: Patients treated with standard chemotherapy for metastatic or relapsed cervical cancer respond poorly to conventional chemotherapy (response achieved in 20–30% of patients) with an overall survival of less than 1 year. High tumour angiogenesis and high concentrations of intratumoural VEG...

Descripción completa

Detalles Bibliográficos
Autores principales: Symonds, R Paul, Gourley, Charlie, Davidson, Susan, Carty, Karen, McCartney, Elaine, Rai, Debbie, Banerjee, Susana, Jackson, David, Lord, Rosemary, McCormack, Mary, Hudson, Emma, Reed, Nicholas, Flubacher, Maxine, Jankowska, Petra, Powell, Melanie, Dive, Caroline, West, Catharine M L, Paul, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lancet Pub. Group 2015
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705431/
https://www.ncbi.nlm.nih.gov/pubmed/26474517
http://dx.doi.org/10.1016/S1470-2045(15)00220-X

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705431/
https://www.ncbi.nlm.nih.gov/pubmed/26474517
http://dx.doi.org/10.1016/S1470-2045(15)00220-X

Ejemplares similares